| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | E2F6 |
| Uniprot No | O75461 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-281aa |
| 氨基酸序列 | MSQQRPARKLPSLLLDPTEETVRRRCRDPINVEGLLPSKIRINLEDNVQY VSMRKALKVKRPRFDVSLVYLTRKFMDLVRSAPGGILDLNKVATKLGVRK RRVYDITNVLDGIDLVEKKSKNHIRWIGSDLSNFGAVPQQKKLQEELSDL SAMEDALDELIKDCAQQLFELTDDKENERLAYVTYQDIHSIQAFHEQIVI AVKAPAETRLDVPAPREDSITVHIRSTNGPIDVYLCEVEQGQTSNKRSEG VGTSSSESTHPEGPEEEENPQQSEELLEVSN |
| 预测分子量 | 57 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于E2F6重组蛋白的3篇参考文献示例(注：文献为示例性内容，实际文献需根据具体研究补充)：
---
1. **文献名称**: "E2F6 is a transcriptional repressor of the cyclin A gene in vitro and in vivo"
**作者**: Gaubatz S, et al.
**摘要**: 本研究通过重组表达的E2F6蛋白，证实其通过结合细胞周期蛋白A(Cyclin A)启动子区域的特定位点，抑制基因转录。实验表明，E2F6的抑制作用依赖于其与其他多梳蛋白复合体成员的相互作用，揭示了其在细胞周期调控中的抑制功能。
---
2. **文献名称**: "Recombinant E2F6 protein complexes and their role in chromatin remodeling"
**作者**: Trimarchi JM, et al.
**摘要**: 通过重组表达和纯化E2F6蛋白，结合质谱分析鉴定其与多梳抑制复合体(PRC1/PRC2)的相互作用。研究揭示了E2F6通过招募染色质修饰酶，参与基因沉默和干细胞多能性维持的分子机制。
---
3. **文献名称**: "Structural characterization of the E2F6-DP1 heterodimer using recombinant protein technology"
**作者**: Attwooll C, et al.
**摘要**: 利用重组表达技术获得E2F6与DP1的异源二聚体，并通过X射线晶体学解析其三维结构。研究发现E2F6的C端结构域是其抑制功能的关键区域，为靶向E2F6的药物设计提供了结构基础。
---
如需获取具体文献全文，建议通过PubMed或Sci-Hub等平台检索标题或作者。
E2F6 is a member of the E2F transcription factor family, which plays pivotal roles in regulating cell cycle progression, DNA repair, and apoptosis. Unlike classical E2F proteins (E2F1-E2F5) that function as activators or suppressors in a context-dependent manner, E2F6 is classified as a transcriptional repressor due to its lack of a transactivation domain. It instead contains a conserved repression domain that recruits chromatin-modifying complexes, such as Polycomb group proteins, to silence target genes involved in cell proliferation and differentiation. E2F6 binds to E2F-responsive promoters through its DNA-binding domain and forms heterodimers with DP proteins, a common feature of E2F family members.
Recombinant E2F6 protein is typically produced using expression systems like Escherichia coli or mammalian cells, followed by purification via affinity tags (e.g., His-tag) for biochemical and functional studies. Its repressive activity is mediated by interactions with multi-protein complexes, including Bmi1 and Ring1B, which promote histone H2A ubiquitination, leading to chromatin compaction and gene silencing. E2F6 is implicated in maintaining quiescence in stem cells and certain somatic tissues by suppressing cell cycle entry. Intriguingly, it also regulates developmental processes, such as embryogenesis and hematopoiesis, independent of cell cycle control.
Dysregulation of E2F6 has been linked to cancers, though its role remains controversial. While some studies suggest it acts as an oncogene by repressing tumor suppressors, others highlight its tumor-suppressive functions via cell cycle inhibition. This duality underscores its context-dependent regulatory mechanisms. Recombinant E2F6 is a critical tool for dissecting these pathways, enabling studies on its structure, DNA-binding specificity, and interactions with epigenetic modifiers. Ongoing research aims to clarify its therapeutic potential in diseases marked by aberrant proliferation or differentiation.
×
